Nuvo Research provides additional information regarding Pennsaid 2%

MISSISSAUGA, ON, March 18, 2013 /PRNewswire/ – Nuvo Research Inc. (Nuvo)
(TSX:NRI) announced today that a Question and Answer document has been
posted on its website to provide additional information to Nuvo
shareholders regarding the regulatory status of Pennsaid 2% in the
United States. Follow this link to access the document – Pennsaid 2% Q&A.

Pennsaid 2%

Pennsaid 2% is the follow-on product to original Pennsaid, a topical
non-steroidal anti-inflammatory drug (NSAID).  Pennsaid 2%, which is
not yet approved by the FDA, contains 2% diclofenac sodium compared to
1.5% for original Pennsaid.  It is more viscous than original Pennsaid,
is supplied in a metered dose pump bottle and is designed to be applied
twice each day compared to four times a day for original PENNSAID.

About Nuvo Research Inc.

Nuvo Research is a publicly traded, Canadian specialty pharmaceutical
company, headquartered in Mississauga, Ontario.  The Company is
building a portfolio of products for the treatment of pain through
internal research and development and by in-licensing and acquisition. 
The Company’s product portfolio includes Pennsaid, Pliaglis(®) and Synera(®).  Pennsaid, a topical nonsteroidal anti-inflammatory drug (NSAID), is
used to treat the signs and symptoms of osteoarthritis of the knee(s). 
PENNSAID is sold in the United States by Mallinckrodt Inc., the
Pharmaceuticals Business of Covidien, in Canada by Paladin Labs Inc.
and in several European countries. Pliaglis is a topical local
anesthetic cream which provides topical local analgesia for superficial
dermatological procedures.  The Company has licensed worldwide
marketing rights to Pliaglis to Galderma Pharma S.A., a global
pharmaceutical company specialized in dermatology which will be
launching Pliaglis in the U.S. and E.U. in the first half of 2013. 
Synera is a topical patch that combines lidocaine, tetracaine and heat,
approved in the United States to provide local dermal analgesia for
superficial venous access and superficial dermatological procedures and
in Europe, for surface anesthesia of normal intact skin.  Nuvo
currently markets Synera in the United States and its licensing
partner, Eurocept International B.V., has initiated a pan-European
launch of Synera (under the name Rapydan(®)) in several European countries.  The Company is also developing the
compound WF10, for the treatment of immune related diseases.

Forward-Looking Statements for Nuvo Research Inc.

This document contains forward-looking statements. Some forward-looking
statements may be identified by words like “expects”, “anticipates”,
“plans”, “intends”, “indicates” or similar expressions. These
forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Nuvo
considers the assumptions on which these forward-looking statements are
based to be reasonable at the time they were prepared, but caution that
these assumptions regarding future events, many of which are beyond the
control of the Company, may ultimately prove to be incorrect. Factors
and risks, which could cause actual results to differ materially from
current expectations, are discussed in the Company’s Annual Report, as
well as in Nuvo’s Annual Information Form for the year ended December
31, 2011.  Nuvo disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information or future events, except as required by law. For additional
information on risks and uncertainties relating to these forward
looking statements, investors should consult the Company’s ongoing
quarterly filings, annual report and Annual Information Form and other
filings found on SEDAR at www.sedar.com.

SOURCE Nuvo Research Inc.